At the inquiry
Qualified leads
Claimants screened against your firm’s BioZorb criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsHologic’s BioZorb implantable marker, used to mark soft tissue such as breast tissue for future procedures, was recalled in October 2024. Claims allege complications such as pain, infection, migration and erosion. We screen claimants against your firm’s criteria.
Discuss a campaignSummary of public information for law firms. Not legal advice.
Delivery models
The right model depends on your intake capacity and acquisition economics.
At the inquiry
Claimants screened against your firm’s BioZorb criteria, delivered with their responses to your intake team or CRM.
For teams that handle follow-up and conversion.
Discuss qualified leadsAt the conversation
Screened claimants connected directly with your intake team during agreed hours and within your delivery caps.
For teams ready to take a live call.
How live transfers workAt the retainer
For select programs, acquisition structured around qualified, completed e-signed retainers.
For firms seeking a retained-client model.
About retainer programsThe litigation · October 2026
Litigation moves quickly. We confirm current status, and whether a program fits your firm’s strategy, before launch.
SourcesA product liability complaint against Hologic was filed in Massachusetts state court. Complaints were later filed for approximately 200 plaintiffs, most in the U.S. District Court for the District of Massachusetts.
Hologic recalled all lots of unused BioZorb Markers, and the FDA classified the recall as Class I, its most serious type. The FDA lists 53,492 devices distributed between April 2019 and April 2024.
Hologic executed a settlement agreement, with no admission of liability, subject to a participation threshold. If conditions are met, it will resolve the substantial majority of BioZorb cases.
Screening
These are the areas BioZorb screening typically covers. The exact questions and thresholds come from your firm.
Talk through your criteriaWhether a BioZorb marker was implanted, with the procedure date and facility, and whether records identify the device.
Reported problems such as pain, infection, rash, migration, erosion or seroma, and whether removal surgery was needed.
The care received for complications and the records available to support the claim.
Whether the claimant is already represented or already part of the existing settlement.
Questions
Answers specific to your program are part of the first conversation.
Hologic executed a settlement in January 2026 intended to resolve the substantial majority of the roughly 200 pending cases, subject to conditions. Whether new claims fit your docket is your firm’s judgment; we confirm program availability with you before launch.
The FDA’s recall notice lists reported adverse events including pain, infection, rash, device migration, device erosion, seroma and discomfort.
Screening can ask about the procedure, its date and facility, and whether the claimant has records identifying the marker. Document requirements are set by your firm.
Where a program requires it, leads can be delivered with a TrustedForm or Jornaya certificate. Call recordings for transfers depend on program support and applicable consent requirements.
Sources
Summary of public information as of October 2026, for law firms evaluating case acquisition. It is not legal advice, and litigation status changes.
Other torts
Start a conversation
Send the practice area, criteria and volume you have in mind. We’ll talk through the right delivery model and a sensible starting point.
Book a 30-minute intro call